Research conducted by the Nomellini Lab utilizes animal models as well as human samples to examine the interaction between the innate and adaptive immune responses that occur after injury or infection, and the heterogeneity of the immune responses that occur in each individual. Led by Vanessa Nomellini, M.D., Ph.D., our lab ultimately aims to develop personalized immune therapies to reverse the immunosuppression that can occur in ICU survivors.

The Reddy Lab focuses on restoring effective antigen presentation to enhance anti-tumor immunity in breast cancers.

Our lab is using various approaches to explore this biology and develop new treatments with a focus on targeting tumor intrinsic factors such as genetic programs like the epithelial to mesenchymal transition that coordinate with infiltrating immune cells in enhance therapeutic resistance and assist distant spread.

The research interests of the Lux Lab lie in the development of novel nanomedicine platforms to diagnose and treat disease in vivo noninvasively.

Our goal is to understand and exploit the immunogenic properties of tumor irradiation in integrating it with immunotherapy to improve cancer patient outcome.